Nasus Pharma (NSRX)

Executive Summary

Nasus Pharma (TASE: NSRX) is a clinical-stage biopharmaceutical company developing intranasal rescue treatments for severe allergic and immune reactions. Its lead candidate, FMXIN002, is a needle-free intranasal epinephrine spray for anaphylaxis, which has completed a Phase I trial. The company is also advancing FMXIN007, an intranasal dexamethasone spray for acute immune-related adverse events, such as those from cancer immunotherapy. Leveraging its proprietary intranasal delivery platform, Nasus addresses high unmet needs in emergency allergy care and immunotherapy management. As a publicly traded company, it operates with a lean pipeline but clear therapeutic focus, positioning for potential partnerships or regulatory milestones. The company's valuation of ~$36M reflects early-stage risk and limited near-term revenue prospects.

Upcoming Catalysts (preview)

• Q2 2026Initiation of Phase II trial for FMXIN002 (intranasal epinephrine)70% success
• Q4 2026Regulatory feedback or filing pathway for FMXIN002 with FDA or EMA50% success
• H2 2026Potential partnership or licensing deal for intranasal platform40% success